Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

organogenesis holdings inc - ORGO

ORGO

Close Chg Chg %
5.18 0.00 0.00%

Closed Market

5.18

0.00 (0.00%)

Volume: 798.49K

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Trade Now

Company Overview: organogenesis holdings inc - ORGO

ORGO Key Data

Open

$5.20

 Day Range

5.12 - 5.35

52 Week Range

2.61 - 7.08

 Market Cap

$657.40M

Shares Outstanding

126.91M

 Public Float

59.06M

Beta

1.47

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.09

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.57M

  

ORGO Performance

1 Week
 
 -1.80%
 
1 Month
 
 0.00%
 
3 Months
 
 20.75%
 
1 Year
 
 61.87%
 
5 Years
 
 -31.21%
 

ORGO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About organogenesis holdings inc - ORGO

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

ORGO At a Glance

Organogenesis Holdings, Inc.
85 Dan Road
Canton, Massachusetts 02021
Phone 1-781-575-0775 Revenue 482.04M
Industry Medical Specialties Net Income 861.00K
Sector Health Technology 2024 Sales Growth 11.29%
Fiscal Year-end 12 / 2025 Employees 869
View SEC Filings

ORGO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 492.308
Price to Sales Ratio 0.874
Price to Book Ratio 1.53
Price to Cash Flow Ratio 29.66
Enterprise Value to EBITDA 9.573
Enterprise Value to Sales 0.935
Total Debt to Enterprise Value 0.096

ORGO Efficiency

Revenue/Employee 554,710.012
Income Per Employee 990.794
Receivables Turnover 4.388
Total Asset Turnover 1.006

ORGO Liquidity

Current Ratio 3.691
Quick Ratio 3.352
Cash Ratio 1.757

ORGO Profitability

Gross Margin 72.429
Operating Margin 4.509
Pretax Margin -0.582
Net Margin 0.179
Return on Assets 0.18
Return on Equity 0.259
Return on Total Capital 0.201
Return on Invested Capital 0.216

ORGO Capital Structure

Total Debt to Total Equity 11.241
Total Debt to Total Capital 10.105
Total Debt to Total Assets 8.699
Long-Term Debt to Equity 13.009
Long-Term Debt to Total Capital 7.979
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Organogenesis Holdings Inc - ORGO

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
468.06M 450.89M 433.14M 482.04M
Sales Growth
+38.36% -3.67% -3.94% +11.29%
Cost of Goods Sold (COGS) incl D&A
118.80M 113.40M 123.35M 132.91M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
16.68M 18.03M 23.45M 25.37M
Depreciation
11.73M 13.15M 18.53M 21.97M
Amortization of Intangibles
4.95M 4.88M 4.92M 3.40M
COGS Growth
+25.33% -4.54% +8.77% +7.75%
Gross Income
349.26M 337.49M 309.79M 349.14M
Gross Income Growth
+43.43% -3.37% -8.21% +12.70%
Gross Profit Margin
+74.62% +74.85% +71.52% +72.43%
2021 2022 2023 2024 5-year trend
SG&A Expense
264.27M 299.07M 286.89M 319.19M
Research & Development
30.74M 39.76M 44.38M 50.27M
Other SG&A
233.52M 259.31M 242.51M 268.92M
SGA Growth
+22.29% +13.17% -4.07% +11.26%
Other Operating Expense
12.08M 9.65M 6.58M 8.21M
Unusual Expense
1.88M 2.27M 3.80M 23.02M
EBIT after Unusual Expense
71.04M 26.50M 12.53M (1.28M)
Non Operating Income/Expense
(13.00K) (4.21M) 57.00K 20.00K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
7.24M 2.01M 2.19M 1.54M
Interest Expense Growth
-35.85% -72.24% +9.01% -29.50%
Gross Interest Expense
7.24M 2.01M 2.19M 1.54M
Interest Capitalized
- - - -
-
Pretax Income
63.79M 20.28M 10.39M (2.81M)
Pretax Income Growth
+245.18% -68.20% -48.76% -127.01%
Pretax Margin
+13.63% +4.50% +2.40% -0.58%
Income Tax
(31.12M) 4.75M 5.45M (3.67M)
Income Tax - Current - Domestic
899.00K 2.75M 3.43M 7.04M
Income Tax - Current - Foreign
(39.00K) 17.00K 3.00K 11.00K
Income Tax - Deferred - Domestic
(31.98M) 1.98M 2.00M (10.75M)
Income Tax - Deferred - Foreign
- - 13.00K 27.00K
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
94.90M 15.53M 4.95M 861.00K
Minority Interest Expense
- - - -
-
Net Income
94.90M 15.53M 4.95M 861.00K
Net Income Growth
+428.73% -83.63% -68.16% -82.59%
Net Margin Growth
+20.28% +3.44% +1.14% +0.18%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
94.90M 15.53M 4.95M 861.00K
Preferred Dividends
- - - -
-
Net Income Available to Common
94.90M 15.53M 4.95M 861.00K
EPS (Basic)
0.7395 0.1194 0.0377 0.0065
EPS (Basic) Growth
+343.88% -83.85% -68.43% -82.76%
Basic Shares Outstanding
128.33M 130.07M 131.23M 131.67M
EPS (Diluted)
0.71 0.1173 0.0372 0.0065
EPS (Diluted) Growth
+326.17% -83.48% -68.29% -82.53%
Diluted Shares Outstanding
133.66M 132.38M 132.75M 131.67M
EBITDA
89.59M 46.80M 39.77M 47.11M
EBITDA Growth
+156.84% -47.76% -15.03% +18.45%
EBITDA Margin
+19.14% +10.38% +9.18% +9.77%

Snapshot

Average Recommendation BUY Average Target Price 7.50
Number of Ratings 2 Current Quarters Estimate -0.08
FY Report Date 03 / 2026 Current Year's Estimate 0.175
Last Quarter’s Earnings 0.216 Median PE on CY Estimate N/A
Year Ago Earnings 0.152 Next Fiscal Year Estimate 0.392
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 2
Mean Estimate -0.08 -0.00 0.18 0.39
High Estimates -0.07 0.00 0.18 0.42
Low Estimate -0.09 -0.01 0.17 0.36
Coefficient of Variance -17.91 -141.43 3.67 10.24

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Organogenesis Holdings Inc - ORGO

Date Name Shares Transaction Value
Mar 7, 2025 Michael J. Driscoll Director 166,879 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.1 per share 851,082.90
Feb 24, 2025 Gary S. Gillheeney President and CEO; Director 732,596 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Prathyusha Durabaibu Director 198,219 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 David Charles Francisco Chief Financial Officer 170,841 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 David Charles Francisco Chief Financial Officer 559,095 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Arthur S. Leibowitz Director 237,186 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Michele I. Korfin Director 190,245 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Antonio S. Montecalvo Vice President, Health Policy 43,956 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Patrick R. Bilbo Chief Operating Officer 190,475 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Patrick R. Bilbo Chief Operating Officer 949,062 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Gilberto Quintero Director 190,245 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Robert Cavorsi Vice President, Strategy 190,463 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Brian Grow Chief Commercial Officer 670,490 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Gary S. Gillheeney President and CEO; Director 3,515,323 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Antonio S. Montecalvo Vice President, Health Policy 196,680 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Robert Cavorsi Vice President, Strategy 63,830 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Lori H. Freedman Chief Admin. and Legal Officer 167,625 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Lori H. Freedman Chief Admin. and Legal Officer 594,195 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Brian Grow Chief Commercial Officer 189,369 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Jon Giacomin Director 192,198 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Organogenesis Holdings Inc in the News